Mofezolac

Summary

Mofezolac (CHEMBL259972) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 339.3 Da · C19H17NO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL259972
Name	Mofezolac
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4237
Molecular formula	C19H17NO5
Molecular weight	339.3
InChIKey	DJEIHHYCDCTAAH-UHFFFAOYSA-N

SMILES: COC1=CC=C(C=C1)C2=C(ON=C2C3=CC=C(C=C3)OC)CC(=O)O

IUPAC name: 2-[3,4-bis(4-methoxyphenyl)-1,2-oxazol-5-yl]acetic acid

Also known as: Mofezolac, Mofezolaco, SID50112817, MOFEZOLAC, SID144206111, mofezolac, MofezolacÊ, MofezolacÂ

Patent coverage: 1,019 distinct patent families (3,937 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2.

Bioactivity

ChEMBL activities: 12 potent at pChembl ≥ 5 of 13 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P05979	8.85	IC50	1.4	nM	CHEMBL_ACT_15256352
PTGS1	8.85	IC50	1.4	nM	CHEMBL_ACT_2160546
PTGS1	8.85	IC50	1.4	nM	CHEMBL_ACT_22817209
P05979	8.1	IC50	7.9	nM	CHEMBL_ACT_18308078
PTGS1	8.1	IC50	7.9	nM	CHEMBL_ACT_18356125
P05979	8.1	IC50	7.9	nM	CHEMBL_ACT_19362621
P05979	8.1	IC50	8	nM	CHEMBL_ACT_25971819
P05979	7.89	IC50	13	nM	CHEMBL_ACT_22803361
Q63921	7.43	AC50	37	nM	CHEMBL_ACT_25175046
P79208	6.36	IC50	440	nM	CHEMBL_ACT_15256349
PTGS2	6.36	IC50	440	nM	CHEMBL_ACT_2160548
PTGS2	6.36	IC50	440	nM	CHEMBL_ACT_22817215

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).